Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of diazepam, a long-acting benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties, and sulindac, a nonsteroidal anti-inflammatory drug (NSAID) used to treat conditions like osteoarthritis and rheumatoid arthritis. This combination has been studied as a therapeutic regimen primarily for rheumatoid arthritis, particularly for nighttime pain relief and morning stiffness. Diazepam works by enhancing gamma-aminobutyric acid activity, while sulindac is a prodrug that is converted in vivo to an active sulfide compound which inhibits prostaglandin synthesis through COX-1 and COX-2 inhibition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diazepam + sulindac.